Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 380

1.

Genetic Alterations at Diagnosis Predict Outcome of AML Patients Age 60 or Older Undergoing Allogeneic Transplantation in First Remission.

Murdock HM, Kim HT, Hambley B, Vachhani P, Denlinger N, Gier SH, Cho C, Perales MA, Koreth J, Ho VT, Soiffer RJ, McCurdy SR, Carroll M, Vasu S, Wang ES, Gondek LP, Devine S, Alyea EP, Gibson CJ, Lindsley RC.

Blood. 2019 Nov 13;134(Supplement_1):48. doi: 10.1182/blood-2019-125967.

PMID:
31724009
2.

Inhibition of Inositol kinase B controls acute and chronic graft-versus-host disease.

Thangavelu G, Du J, Paz KG, Loschi M, Zaiken MC, Flynn R, Taylor PA, Kirchmeier AK, Panoskaltsis-Mortari A, Luznik L, MacDonald KP, Hill GR, Maillard I, Munn DH, Serody JS, Murphy WJ, Miklos D, Cutler CS, Koreth J, Antin JH, Soiffer RJ, Ritz J, Dahlberg C, Miller AT, Blazar BR.

Blood. 2019 Oct 15. pii: blood.2019000032. doi: 10.1182/blood.2019000032. [Epub ahead of print]

PMID:
31697815
3.

Incidence, predictors, and outcomes of veno-occlusive disease/sinusoidal obstruction syndrome after reduced intensity allogeneic hematopoietic cell transplantation.

Lewis C, Kim HT, Roeker LE, Cutler C, Koreth J, Nikiforow S, Armand P, Gootpu M, Romee R, Glotzbecker B, Nageshwar P, Antin JH, Alyea EP, Richardson P, Soiffer RJ, Ho VT.

Biol Blood Marrow Transplant. 2019 Oct 31. pii: S1083-8791(19)30706-2. doi: 10.1016/j.bbmt.2019.10.024. [Epub ahead of print]

PMID:
31678537
4.

A phase II study of reduced intensity double umbilical cord blood transplantation using fludarabine, melphalan, and low dose total body irradiation.

DeFilipp Z, Li S, Avigan D, Armand P, Ho VT, Koreth J, Nikiforow S, Alyea EP, Ritz J, Boussiotis V, Rosenblatt J, Brown J, McAfee S, Dey BR, El-Jawahri A, Spitzer TR, Chen YB, Soiffer RJ, Antin JH, Ballen KK, Cutler CS.

Bone Marrow Transplant. 2019 Oct 15. doi: 10.1038/s41409-019-0715-x. [Epub ahead of print]

PMID:
31616065
5.

Prophylactic, preemptive, and curative treatment for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a position statement from an international expert group.

Mohty M, Malard F, Abecasis M, Aerts E, Alaskar AS, Aljurf M, Arat M, Bader P, Baron F, Basak G, Bazarbachi A, Blaise D, Ciceri F, Corbacioglu S, Dalle JH, Dignan F, Fukuda T, Huynh A, Kuball J, Lachance S, Lazarus H, Masszi T, Michallet M, Nagler A, NiChonghaile M, Okamoto S, Pagliuca A, Peters C, Petersen FB, Richardson PG, Ruutu T, Saber W, Savani BN, Soiffer R, Styczynski J, Wallhult E, Yakoub-Agha I, Duarte RF, Carreras E.

Bone Marrow Transplant. 2019 Oct 1. doi: 10.1038/s41409-019-0705-z. [Epub ahead of print] No abstract available.

PMID:
31576023
6.

A Phase 3 Randomized Study of Remestemcel-L versus Placebo Added to Second-Line Therapy in Patients with Steroid-Refractory Acute Graft-versus-Host Disease.

Kebriaei P, Hayes J, Daly A, Uberti J, Marks DI, Soiffer R, Waller EK, Burke E, Skerrett D, Shpall E, Martin PJ.

Biol Blood Marrow Transplant. 2019 Sep 7. pii: S1083-8791(19)30573-7. doi: 10.1016/j.bbmt.2019.08.029. [Epub ahead of print]

PMID:
31505228
7.

Dose-escalated interleukin-2 therapy for refractory chronic graft-versus-host disease in adults and children.

Whangbo JS, Kim HT, Mirkovic N, Leonard L, Poryanda S, Silverstein S, Kim S, Reynolds CG, Rai SC, Verrill K, Lee MA, Margossian S, Duncan C, Lehmann L, Huang J, Nikiforow S, Alyea EP 3rd, Armand P, Cutler CS, Ho VT, Blazar BR, Antin JH, Soiffer RJ, Ritz J, Koreth J.

Blood Adv. 2019 Sep 10;3(17):2550-2561. doi: 10.1182/bloodadvances.2019000631.

8.

Checkpoint inhibition to prevent or treat relapse in allogeneic hematopoietic cell transplantation.

Soiffer RJ.

Bone Marrow Transplant. 2019 Aug;54(Suppl 2):798-802. doi: 10.1038/s41409-019-0617-y. Review.

PMID:
31431704
9.

Allogeneic Stem Cell Transplantation Provides Durable Remission in Patients with Primary Mediastinal Large B Cell Lymphoma.

Herrera AF, Chen L, Khajavian S, Chase M, Darrah J, Maloney D, Ho VT, Soiffer RJ, Antin JH, Forman SJ, Nademanee AP, Chen YB, Armand P, Shadman M.

Biol Blood Marrow Transplant. 2019 Aug 5. pii: S1083-8791(19)30513-0. doi: 10.1016/j.bbmt.2019.07.041. [Epub ahead of print]

PMID:
31394277
10.

Recurrent genetic HLA loss in AML relapsed after matched unrelated allogeneic hematopoietic cell transplantation.

Jan M, Leventhal MJ, Morgan EA, Wengrod JC, Nag A, Drinan SD, Wollison BM, Ducar MD, Thorner AR, Leppanen S, Baronas J, Stevens J, Lane WJ, Kekre N, Ho VT, Koreth J, Cutler CS, Nikiforow S, Alyea EP 3rd, Antin JH, Soiffer RJ, Ritz J, Lindsley RC, Ebert BL.

Blood Adv. 2019 Jul 23;3(14):2199-2204. doi: 10.1182/bloodadvances.2019000445.

11.

Effect of Sirolimus on Immune Reconstitution Following Myeloablative Allogeneic Stem Cell Transplantation: An Ancillary Analysis of a Randomized Controlled Trial Comparing Tacrolimus/Sirolimus and Tacrolimus/Methotrexate (Blood and Marrow Transplant Clinical Trials Network/BMT CTN 0402).

Gooptu M, Kim HT, Howard A, Choi SW, Soiffer RJ, Antin JH, Ritz J, Cutler CS.

Biol Blood Marrow Transplant. 2019 Jul 2. pii: S1083-8791(19)30413-6. doi: 10.1016/j.bbmt.2019.06.029. [Epub ahead of print]

PMID:
31271885
12.

Gait speed, grip strength, and clinical outcomes in older patients with hematologic malignancies.

Liu MA, DuMontier C, Murillo A, Hshieh TT, Bean JF, Soiffer RJ, Stone RM, Abel GA, Driver JA.

Blood. 2019 Jul 25;134(4):374-382. doi: 10.1182/blood.2019000758. Epub 2019 Jun 5.

PMID:
31167800
13.

Progression Risk Stratification of Asymptomatic Waldenström Macroglobulinemia.

Bustoros M, Sklavenitis-Pistofidis R, Kapoor P, Liu CJ, Kastritis E, Zanwar S, Fell G, Abeykoon JP, Hornburg K, Neuse CJ, Marinac CR, Liu D, Soiffer J, Gavriatopoulou M, Boehner C, Cappuccio JM, Dumke H, Reyes K, Soiffer RJ, Kyle RA, Treon SP, Castillo JJ, Dimopoulos MA, Ansell SM, Trippa L, Ghobrial IM.

J Clin Oncol. 2019 Jun 1;37(16):1403-1411. doi: 10.1200/JCO.19.00394. Epub 2019 Apr 16.

PMID:
30990729
14.

Function, Survival, and Care Utilization Among Older Adults With Hematologic Malignancies.

DuMontier C, Liu MA, Murillo A, Hshieh T, Javedan H, Soiffer R, Stone RM, Driver JA, Abel GA.

J Am Geriatr Soc. 2019 May;67(5):889-897. doi: 10.1111/jgs.15835. Epub 2019 Apr 4.

PMID:
30945759
15.

Functional analysis of clinical response to low-dose IL-2 in patients with refractory chronic graft-versus-host disease.

Whangbo JS, Kim HT, Nikiforow S, Koreth J, Alho AC, Falahee B, Kim S, Dusenbury K, Fields MJ, Reynolds CG, Alyea EP 3rd, Armand P, Cutler CS, Ho VT, Antin JH, Soiffer RJ, Ritz J.

Blood Adv. 2019 Apr 9;3(7):984-994. doi: 10.1182/bloodadvances.2018027474.

16.

Efficacy and immunologic effects of extracorporeal photopheresis plus interleukin-2 in chronic graft-versus-host disease.

Belizaire R, Kim HT, Poryanda SJ, Mirkovic NV, Hipolito E, Savage WJ, Reynolds CG, Fields MJ, Whangbo J, Kubo T, Nikiforow S, Alyea EP, Armand P, Cutler CS, Ho VT, Blazar BR, Antin JH, Ritz J, Soiffer RJ, Koreth J.

Blood Adv. 2019 Apr 9;3(7):969-979. doi: 10.1182/bloodadvances.2018029124.

17.

Targeting PI3Kδ function for amelioration of murine chronic graft-versus-host disease.

Paz K, Flynn R, Du J, Tannheimer S, Johnson AJ, Dong S, Stark AK, Okkenhaug K, Panoskaltsis-Mortari A, Sage PT, Sharpe AH, Luznik L, Ritz J, Soiffer RJ, Cutler CS, Koreth J, Antin JH, Miklos DB, MacDonald KP, Hill GR, Maillard I, Serody JS, Murphy WJ, Munn DH, Feser C, Zaiken M, Vanhaesebroeck B, Turka LA, Byrd JC, Blazar BR.

Am J Transplant. 2019 Jun;19(6):1820-1830. doi: 10.1111/ajt.15305. Epub 2019 Mar 19.

PMID:
30748099
18.

Whole blood RNA sequencing reveals a unique transcriptomic profile in patients with ARDS following hematopoietic stem cell transplantation.

Englert JA, Cho MH, Lamb AE, Shumyatcher M, Barragan-Bradford D, Basil MC, Higuera A, Isabelle C, Vera MP, Dieffenbach PB, Fredenburgh LE, Kang JB, Bhatt AS, Antin JH, Ho VT, Soiffer RJ, Howrylak JA, Himes BE, Baron RM.

Respir Res. 2019 Jan 21;20(1):15. doi: 10.1186/s12931-019-0981-6.

19.

Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma.

Baumeister SH, Murad J, Werner L, Daley H, Trebeden-Negre H, Gicobi JK, Schmucker A, Reder J, Sentman CL, Gilham DE, Lehmann FF, Galinsky I, DiPietro H, Cummings K, Munshi NC, Stone RM, Neuberg DS, Soiffer R, Dranoff G, Ritz J, Nikiforow S.

Cancer Immunol Res. 2019 Jan;7(1):100-112. doi: 10.1158/2326-6066.CIR-18-0307. Epub 2018 Nov 5.

PMID:
30396908
20.

Evaluating the adverse effects of melphalan formulations.

Xiang E, Ni J, Glotzbecker B, Laubach J, Soiffer R, McDonnell AM.

J Oncol Pharm Pract. 2019 Oct;25(7):1631-1637. doi: 10.1177/1078155218804042. Epub 2018 Oct 18.

PMID:
30336728
21.

Small-molecule BCL6 inhibitor effectively treats mice with nonsclerodermatous chronic graft-versus-host disease.

Paz K, Flynn R, Du J, Qi J, Luznik L, Maillard I, MacDonald KP, Hill GR, Serody JS, Murphy WJ, Sage PT, Sharpe AH, Miklos D, Cutler CS, Koreth J, Antin JH, Soiffer RJ, Ritz J, Bradner JE, Melnick AM, Blazar BR.

Blood. 2019 Jan 3;133(1):94-99. doi: 10.1182/blood-2018-03-839993. Epub 2018 Oct 2.

PMID:
30279226
22.

Early Clinical Predictors of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Myeloablative Stem Cell Transplantation.

Roeker LE, Kim HT, Glotzbecker B, Nageshwar P, Nikiforow S, Koreth J, Armand P, Cutler C, Alyea EP, Antin JH, Richardson PG, Soiffer RJ, Ho VT.

Biol Blood Marrow Transplant. 2019 Jan;25(1):137-144. doi: 10.1016/j.bbmt.2018.07.039. Epub 2018 Aug 3.

PMID:
30081073
23.

Effect of Antihuman T Lymphocyte Globulin on Immune Recovery after Myeloablative Allogeneic Stem Cell Transplantation with Matched Unrelated Donors: Analysis of Immune Reconstitution in a Double-Blind Randomized Controlled Trial.

Gooptu M, Kim HT, Chen YB, Rybka W, Artz A, Boyer M, Johnston L, McGuirk J, Shea TC, Jagasia M, Shaughnessy PJ, Reynolds CG, Fields M, Alyea EP, Ho VT, Glavin F, Dipersio JF, Westervelt P, Ritz J, Soiffer RJ.

Biol Blood Marrow Transplant. 2018 Nov;24(11):2216-2223. doi: 10.1016/j.bbmt.2018.07.002. Epub 2018 Jul 10.

24.

Cytomegalovirus Infection Among Cord Blood Allogeneic Transplantation Recipients: Low Incidence of Cytomegalovirus Events without High-Dose Valacyclovir Prophylaxis.

Knoll BM, Peixoto D, Koo S, Hammond SP, Ho VT, Antin JH, Soiffer RJ, Cutler C, Marty FM.

Biol Blood Marrow Transplant. 2018 Oct;24(10):2164-2165. doi: 10.1016/j.bbmt.2018.06.029. Epub 2018 Jun 30. No abstract available.

25.

Integrated genomic characterization of oral carcinomas in post-hematopoietic stem cell transplantation survivors.

Hanna GJ, Kofman ER, Shazib MA, Woo SB, Reardon B, Treister NS, Haddad RI, Cutler CS, Antin JH, Van Allen EM, Uppaluri R, Soiffer RJ.

Oral Oncol. 2018 Jun;81:1-9. doi: 10.1016/j.oraloncology.2018.04.007. Epub 2018 Apr 10.

PMID:
29884406
26.

Can IL-15 superagonist ALTer GVL?

Soiffer RJ.

Blood. 2018 Jun 7;131(23):2511-2512. doi: 10.1182/blood-2018-04-840835. No abstract available.

PMID:
29880647
27.

Defibrotide for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome following nontransplant-associated chemotherapy: Final results from a post hoc analysis of data from an expanded-access program.

Kernan NA, Richardson PG, Smith AR, Triplett BM, Antin JH, Lehmann L, Messinger Y, Liang W, Hume R, Tappe W, Soiffer RJ, Grupp SA.

Pediatr Blood Cancer. 2018 Oct;65(10):e27269. doi: 10.1002/pbc.27269. Epub 2018 Jun 6.

28.

Related donor transplants: has posttransplantation cyclophosphamide nullified the detrimental effect of HLA mismatch?

Robinson TM, Fuchs EJ, Zhang MJ, St Martin A, Labopin M, Keesler DA, Blaise D, Bashey A, Bourhis JH, Ciceri F, Ciurea SO, Devine SM, Mohty M, McCurdy SR, Milpied N, McNiece IK, Rocha V, Romee R, Socie G, Yakoub-Agha I, Soiffer RJ, Eapen M, Nagler A; Acute Leukemia Working Party of the European Society for Blood and Marrow Transplant and the Center for International Blood and Marrow Transplant Research.

Blood Adv. 2018 Jun 12;2(11):1180-1186. doi: 10.1182/bloodadvances.2018018291.

29.

Final results from a defibrotide treatment-IND study for patients with hepatic veno-occlusive disease/sinusoidal obstruction syndrome.

Kernan NA, Grupp S, Smith AR, Arai S, Triplett B, Antin JH, Lehmann L, Shore T, Ho VT, Bunin N, Iacobelli M, Liang W, Hume R, Tappe W, Soiffer R, Richardson P.

Br J Haematol. 2018 Jun;181(6):816-827. doi: 10.1111/bjh.15267. Epub 2018 May 16.

30.

Impact of Thrombotic Microangiopathy on Renal Outcomes and Survival after Hematopoietic Stem Cell Transplantation.

Postalcioglu M, Kim HT, Obut F, Yilmam OA, Yang J, Byun BC, Kupiec-Weglinski S, Soiffer R, Ritz J, Antin JH, Alyea E, Koreth J, Cutler C, Armand P, Paik JM, Leaf DE, Ho VT, Abdi R.

Biol Blood Marrow Transplant. 2018 Nov;24(11):2344-2353. doi: 10.1016/j.bbmt.2018.05.010. Epub 2018 May 11.

31.

High NPM1-mutant allele burden at diagnosis predicts unfavorable outcomes in de novo AML.

Patel SS, Kuo FC, Gibson CJ, Steensma DP, Soiffer RJ, Alyea EP 3rd, Chen YA, Fathi AT, Graubert TA, Brunner AM, Wadleigh M, Stone RM, DeAngelo DJ, Nardi V, Hasserjian RP, Weinberg OK.

Blood. 2018 Jun 21;131(25):2816-2825. doi: 10.1182/blood-2018-01-828467. Epub 2018 May 3.

32.

A Comparison of the Myeloablative Conditioning Regimen Fludarabine/Busulfan with Cyclophosphamide/Total Body Irradiation, for Allogeneic Stem Cell Transplantation in the Modern Era: A Cohort Analysis.

Gooptu M, Kim HT, Ho VT, Alyea EP, Koreth J, Armand P, Ritz J, Nikiforow S, Glotzbecker BE, Nageshwar P, Soiffer RJ, Antin JH, Cutler CS.

Biol Blood Marrow Transplant. 2018 Aug;24(8):1733-1740. doi: 10.1016/j.bbmt.2018.03.011. Epub 2018 Mar 16.

33.

Phase 1 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease.

Nahas MR, Soiffer RJ, Kim HT, Alyea EP 3rd, Arnason J, Joyce R, Antin JH, Ho VT, Stroopinsky D, Li S, Levine JD, McMasters M, Jain S, Hamdan A, Tzachanis D, Bryant MP, Logan EK, Bazemore J, Stewart J, Joyce A, Stephenson S, Washington A, Cole L, Pyzer A, Leaf RK, Avigan DE, Rosenblatt J.

Blood. 2018 Jun 21;131(25):2836-2845. doi: 10.1182/blood-2017-05-780239. Epub 2018 Mar 16.

PMID:
29549175
34.

Prevalence of Cognitive Impairment and Association With Survival Among Older Patients With Hematologic Cancers.

Hshieh TT, Jung WF, Grande LJ, Chen J, Stone RM, Soiffer RJ, Driver JA, Abel GA.

JAMA Oncol. 2018 May 1;4(5):686-693. doi: 10.1001/jamaoncol.2017.5674.

35.

Financial Hardship after Hematopoietic Cell Transplantation: Lack of Impact on Survival.

Khera N, Albelda R, Hahn T, Coronado DS, Odejide OO, Soiffer RJ, Abel GA.

Cancer Epidemiol Biomarkers Prev. 2018 Mar;27(3):345-347. doi: 10.1158/1055-9965.EPI-17-1040. Epub 2018 Feb 13.

36.

α1-Antitrypsin infusion for treatment of steroid-resistant acute graft-versus-host disease.

Magenau JM, Goldstein SC, Peltier D, Soiffer RJ, Braun T, Pawarode A, Riwes MM, Kennel M, Antin JH, Cutler CS, Ho VT, Alyea EP 3rd, Parkin BL, Yanik GA, Choi SW, Lewis EC, Dinarello CA, Koreth J, Reddy P.

Blood. 2018 Mar 22;131(12):1372-1379. doi: 10.1182/blood-2017-11-815746. Epub 2018 Feb 2.

37.

Reply to J.J. Boelens et al.

Soiffer RJ, Chen YA, Jagasia MH.

J Clin Oncol. 2018 Apr 10;36(11):1176-1177. doi: 10.1200/JCO.2017.77.2939. Epub 2018 Feb 7. No abstract available.

PMID:
29412783
38.

Tyrosine kinase inhibitors and immune checkpoint blockade in allogeneic hematopoietic cell transplantation.

Soiffer RJ, Davids MS, Chen YB.

Blood. 2018 Mar 8;131(10):1073-1080. doi: 10.1182/blood-2017-10-752154. Epub 2018 Jan 22. Review.

PMID:
29358177
39.

Neurocognitive dysfunction in hematopoietic cell transplant recipients: expert review from the late effects and Quality of Life Working Committee of the CIBMTR and complications and Quality of Life Working Party of the EBMT.

Buchbinder D, Kelly DL, Duarte RF, Auletta JJ, Bhatt N, Byrne M, DeFilipp Z, Gabriel M, Mahindra A, Norkin M, Schoemans H, Shah AJ, Ahmed I, Atsuta Y, Basak GW, Beattie S, Bhella S, Bredeson C, Bunin N, Dalal J, Daly A, Gajewski J, Gale RP, Galvin J, Hamadani M, Hayashi RJ, Adekola K, Law J, Lee CJ, Liesveld J, Malone AK, Nagler A, Naik S, Nishihori T, Parsons SK, Scherwath A, Schofield HL, Soiffer R, Szer J, Twist I, Warwick AB, Wirk BM, Yi J, Battiwalla M, Flowers MDE, Savani B, Shaw BE.

Bone Marrow Transplant. 2018 May;53(5):535-555. doi: 10.1038/s41409-017-0055-7. Epub 2018 Jan 17. Review.

40.

Bortezomib-based immunosuppression after reduced-intensity conditioning hematopoietic stem cell transplantation: randomized phase II results.

Koreth J, Kim HT, Lange PB, Poryanda SJ, Reynolds CG, Rai SC, Armand P, Cutler CS, Ho VT, Glotzbecker B, Yusuf R, Nikiforow S, Chen YB, Dey B, McMasters M, Ritz J, Blazar BR, Soiffer RJ, Antin JH, Alyea EP 3rd.

Haematologica. 2018 Mar;103(3):522-530. doi: 10.3324/haematol.2017.176859. Epub 2018 Jan 11.

41.

Pharmacologic agents to prevent and treat relapse after allogeneic hematopoietic cell transplantation.

Soiffer RJ, Chen YB.

Blood Adv. 2017 Nov 28;1(25):2473-2482. doi: 10.1182/bloodadvances.2017009894. eCollection 2017 Nov 28. Review. No abstract available.

42.

Vaccination with autologous myeloblasts admixed with GM-K562 cells in patients with advanced MDS or AML after allogeneic HSCT.

Ho VT, Kim HT, Bavli N, Mihm M, Pozdnyakova O, Piesche M, Daley H, Reynolds C, Souders NC, Cutler C, Koreth J, Alyea EP, Antin JH, Ritz J, Dranoff G, Soiffer RJ.

Blood Adv. 2017 Nov 14;1(24):2269-2279. doi: 10.1182/bloodadvances.2017009084. eCollection 2017 Nov 14.

43.

Pharmacologic agents to prevent and treat relapse after allogeneic hematopoietic cell transplantation.

Soiffer RJ, Chen YB.

Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):699-707. doi: 10.1182/asheducation-2017.1.699. Review. No abstract available.

44.

Immunohistopathological characterization and the impact of topical immunomodulatory therapy in oral chronic graft-versus-host disease: A pilot study.

Motta A, Zhan Q, Larson A, Lerman M, Woo SB, Soiffer RJ, Murphy GF, Treister NS.

Oral Dis. 2018 May;24(4):580-590. doi: 10.1111/odi.12813. Epub 2018 Mar 13.

45.

Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma.

Herrera AF, Rodig SJ, Song JY, Kim Y, Griffin GK, Yang D, Nikolaenko L, Mei M, Bedell V, Dal Cin P, Pak C, Alyea EP, Budde LE, Chen R, Chen YB, Chan WC, Cutler CS, Ho VT, Koreth J, Krishnan A, Murata-Collins JL, Nikiforow S, Palmer J, Pihan GA, Pillai R, Popplewell L, Rosen ST, Siddiqi T, Sohani AR, Zain J, Kwak LW, Weisenburger DD, Weinstock DM, Soiffer RJ, Antin JH, Forman SJ, Nademanee AP, Armand P.

Biol Blood Marrow Transplant. 2018 Mar;24(3):514-520. doi: 10.1016/j.bbmt.2017.11.023. Epub 2017 Nov 28.

46.

Antibodies targeting surface membrane antigens in patients with chronic graft-versus-host disease.

Wang KS, Kim HT, Nikiforow S, Heubeck AT, Ho VT, Koreth J, Alyea EP, Armand P, Blazar BR, Soiffer RJ, Antin JH, Cutler CS, Ritz J.

Blood. 2017 Dec 28;130(26):2889-2899. doi: 10.1182/blood-2017-08-801001. Epub 2017 Nov 14.

47.

Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti-T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease-Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplantation.

Soiffer RJ, Kim HT, McGuirk J, Horwitz ME, Johnston L, Patnaik MM, Rybka W, Artz A, Porter DL, Shea TC, Boyer MW, Maziarz RT, Shaughnessy PJ, Gergis U, Safah H, Reshef R, DiPersio JF, Stiff PJ, Vusirikala M, Szer J, Holter J, Levine JD, Martin PJ, Pidala JA, Lewis ID, Ho VT, Alyea EP, Ritz J, Glavin F, Westervelt P, Jagasia MH, Chen YB.

J Clin Oncol. 2017 Dec 20;35(36):4003-4011. doi: 10.1200/JCO.2017.75.8177. Epub 2017 Oct 17.

PMID:
29040031
48.

Neurocognitive Dysfunction in Hematopoietic Cell Transplant Recipients: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Complications and Quality of Life Working Party of the European Society for Blood and Marrow Transplantation.

Kelly DL, Buchbinder D, Duarte RF, Auletta JJ, Bhatt N, Byrne M, DeFilipp Z, Gabriel M, Mahindra A, Norkin M, Schoemans H, Shah AJ, Ahmed I, Atsuta Y, Basak GW, Beattie S, Bhella S, Bredeson C, Bunin N, Dalal J, Daly A, Gajewski J, Gale RP, Galvin J, Hamadani M, Hayashi RJ, Adekola K, Law J, Lee CJ, Liesveld J, Malone AK, Nagler A, Naik S, Nishihori T, Parsons SK, Scherwath A, Schofield HL, Soiffer R, Szer J, Twist I, Warwick A, Wirk BM, Yi J, Battiwalla M, Flowers ME, Savani B, Shaw BE.

Biol Blood Marrow Transplant. 2018 Feb;24(2):228-241. doi: 10.1016/j.bbmt.2017.09.004. Epub 2017 Sep 20. Review.

49.

Oral health status and risk of bacteremia following allogeneic hematopoietic cell transplantation.

Sultan AS, Zimering Y, Petruzziello G, Alyea EP 3rd, Antin JH, Soiffer RJ, Ho VT, Sonis ST, Woo SB, Marty FM, Treister NS.

Oral Surg Oral Med Oral Pathol Oral Radiol. 2017 Sep;124(3):253-260. doi: 10.1016/j.oooo.2017.06.003. Epub 2017 Jun 16.

PMID:
28823316
50.

Mobilized Peripheral Blood Stem Cells Versus Unstimulated Bone Marrow As a Graft Source for T-Cell-Replete Haploidentical Donor Transplantation Using Post-Transplant Cyclophosphamide.

Bashey A, Zhang MJ, McCurdy SR, St Martin A, Argall T, Anasetti C, Ciurea SO, Fasan O, Gaballa S, Hamadani M, Munshi P, Al Malki MM, Nakamura R, O'Donnell PV, Perales MA, Raj K, Romee R, Rowley S, Rocha V, Salit RB, Solh M, Soiffer RJ, Fuchs EJ, Eapen M.

J Clin Oncol. 2017 Sep 10;35(26):3002-3009. doi: 10.1200/JCO.2017.72.8428. Epub 2017 Jun 23. Erratum in: J Clin Oncol. 2019 Feb 20;37(6):528.

Supplemental Content

Loading ...
Support Center